Mometazona Atb (Mometasone Furoate)

Mometazona Atb is a topical corticosteroid used to manage inflammatory skin disorders.

• Eczema: reduces redness, itching and swelling associated with atopic dermatitis.
• Psoriasis: helps clear plaques and diminishes scaling and inflammation.
• Dermatitis: alleviates symptoms of contact and seborrheic dermatitis by suppressing local immune responses.

• Mometasone Furoate binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action down‑regulates pro‑inflammatory cytokines, inhibits phospholipase A2, and reduces leukocyte migration, resulting in potent anti‑inflammatory and immunosuppressive effects in the skin.

Topical application of Mometazona Atb may cause local skin reactions.

Common Side Effects

• Burning or stinging sensation at the application site.
• Itching or mild irritation.
• Dryness or peeling of the skin.
• Erythema or mild redness.
• Folliculitis or small pustules.
• Pruritus.

Serious or Rare Side Effects

• Skin atrophy or thinning.
• Telangiectasia (visible small blood vessels).
• Secondary bacterial, fungal or viral infection.
• Systemic adrenal suppression with extensive use.
• Allergic contact dermatitis or hypersensitivity reactions.
• Delayed wound healing.

Before using Mometazona Atb, consider the following safety measures.

• Duration of Use: limit treatment to the shortest period necessary, typically no longer than 2‑4 weeks.
• Occlusive Dressings: avoid covering treated areas with airtight dressings unless directed by a clinician.
• Infected Skin: do not apply to skin with active bacterial, viral or fungal infections without medical advice.
• Broken Skin: avoid use on open wounds, abrasions or severe eczema lesions.
• Pediatric Use: use with caution in children; monitor for growth‑related side effects.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mometazona Atb may interact with other medications applied to the skin or systemic agents.

Major Interactions (Avoid)

• Systemic corticosteroids: concurrent use can increase risk of systemic adrenal suppression.
• Potent CYP3A4 inhibitors applied topically: may raise local drug concentration.
• Live vaccines: topical steroids may diminish local immune response to vaccination sites.

Moderate Interactions (Monitor Closely)

• Topical antibiotics or antifungals: monitor for additive irritation.
• Other topical steroids: avoid overlapping applications to reduce cumulative potency.
• Immunosuppressants: may enhance immunosuppressive effect on skin.
• Skin care products containing alcohol or astringents: can increase irritation risk.